AUTHORS: Collij L. E., Bollack A., La Joie R., Shekari M., Bullich S., Roé-Vellvé N., Koglin N., Jovalekic A., Garciá D. V., Drzezga A., Garibotto V., Stephens A. W., Battle M., Buckley C., Barkhof F., Farrar G., Gispert J. D.
Alzheimer's & Dementia, 20(12): 9037-9048, 20 November 2024
ABSTRACT
Amyloid-PET quantification through the tracer-independent Centiloid (CL) scale has emerged as an essential tool for the accurate measurement of amyloid-β (Aβ) pathology in Alzheimer’s disease (AD) patients. The AMYPAD consortium set out to integrate existing literature and recent work from the consortium to provide clinical context-of-use recommendations for the CL scale. Compared to histopathology, visual reads, and cerebrospinal fluid, CL quantification accurately reflects the amount of AD pathology. With high certainty, a CL value below 10 excludes the presence of Aβ pathology, while a value above 30 corresponds well with pathological amounts. Values falling in between these two cutoffs (“intermediate range”) are related to an increased risk of disease progression. Together, CL quantification is a valuable adjunct to visual assessments of amyloid-PET images. An abnormal amyloid biomarker assessment is a key criterion to determine eligibility for anti-amyloid disease-modifying therapies, and amyloid-PET quantification can add further value by precisely monitoring amyloid clearance, and hence guiding patient management decisions.
Highlights
- Centiloid (CL) quantification robustly reflects of the amount of Aβ pathology.
- CL < 10/CL > 30 reflects Aβ-negativity/positivity thresholds with high certainty.
- CL quantification is a valuable adjunct to visual assessments of amyloid-PET.
- CL quantification can support trial design and treatment management.
- CL quantification could support the identification of early or emerging Aβ pathology.
BibTex
https://doi.org/10.1002/alz.14336
Module: PET
